Literature DB >> 26135560

Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling.

Ji Yuan1, George Wright, Andreas Rosenwald, Christian Steidl, Randy D Gascoyne, Joseph M Connors, Anja Mottok, Dennis D Weisenburger, Timothy C Greiner, Kai Fu, Lynette Smith, Lisa M Rimsza, Elaine S Jaffe, Elias Campo, Antonio Martinez, Jan Delabie, Rita M Braziel, James R Cook, German Ott, Julie M Vose, Louis M Staudt, Wing C Chan.   

Abstract

Mediastinal involvement is considered essential for the diagnosis of primary mediastinal large B-cell lymphoma (PMBL). However, we have observed cases of diffuse large B-cell lymphoma (DLBCL) with features of PMBL but without detectable mediastinal involvement. The goal was to assess our previously established gene expression profiling (GEP) signature for PMBL in classifying these cases. In a large series of DLBCL cases, we identified 24 cases with a GEP signature of PMBL, including 9 cases with a submission diagnosis of DLBCL consistent with PMBL (G-PMBL-P) and 15 cases with a submission diagnosis of DLBCL. The pathology reviewers agreed with the diagnosis in the 9 G-PMBL-P cases. Among the other 15 DLBCL cases, 11 were considered to be PMBL or DLBCL consistent with PMBL, 3 were considered to be DLBCL, and 1 case was a gray-zone lymphoma with features intermediate between DLBCL and classical Hodgkin lymphoma. All 9 G-PMBL-P and 9 of the 15 DLBCL cases (G-PMBL-M) had demonstrated mediastinal involvement at presentation. Interestingly, 6 of the 15 DLBCL cases (G-PMBL-NM) had no clinical or radiologic evidence of mediastinal involvement. The 3 subgroups of PMBL had otherwise similar clinical characteristics, and there were no significant differences in overall survival. Genetic alterations of CIITA and PDL1/2 were detected in 26% and 40% of cases, respectively, including 1 G-PMBL-NM case with gain of PDL1/2. In conclusion, PMBL can present as a nonmediastinal tumor without evidence of mediastinal involvement, and GEP offers a more precise diagnosis of PMBL.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26135560      PMCID: PMC7742851          DOI: 10.1097/PAS.0000000000000473

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  30 in total

1.  Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children.

Authors:  Ilske Oschlies; Birgit Burkhardt; Itziar Salaverria; Andreas Rosenwald; Emanuele S G d'Amore; Monika Szczepanowski; Karoline Koch; Martin L Hansmann; Harald Stein; Peter Möller; Alfred Reiter; Martin Zimmermann; Angelo Rosolen; Reiner Siebert; Elaine S Jaffe; Wolfram Klapper
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

2.  Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain.

Authors:  Min Shi; Margaretha G M Roemer; Bjoern Chapuy; Xiaoyun Liao; Heather Sun; Geraldine S Pinkus; Margaret A Shipp; Gordon J Freeman; Scott J Rodig
Journal:  Am J Surg Pathol       Date:  2014-12       Impact factor: 6.394

3.  Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene.

Authors:  S Joos; M I Otaño-Joos; S Ziegler; S Brüderlein; S du Manoir; M Bentz; P Möller; P Lichter
Journal:  Blood       Date:  1996-02-15       Impact factor: 22.113

4.  Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA ("Groupe d'Etude des Lymphomes de l'Adulte") study.

Authors:  D Cazals-Hatem; E Lepage; P Brice; A Ferrant; M F d'Agay; E Baumelou; J Brière; M Blanc; P Gaulard; P Biron; D Schlaifer; J Diebold; J Audouin
Journal:  Am J Surg Pathol       Date:  1996-07       Impact factor: 6.394

5.  Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience.

Authors:  K J Savage; N Al-Rajhi; N Voss; C Paltiel; R Klasa; R D Gascoyne; J M Connors
Journal:  Ann Oncol       Date:  2005-10-19       Impact factor: 32.976

6.  Primary mediastinal large B-cell lymphoma segregating in a family: exome sequencing identifies MLL as a candidate predisposition gene.

Authors:  Silva Saarinen; Eevi Kaasinen; Marja-Liisa Karjalainen-Lindsberg; Kari Vesanen; Mervi Aavikko; Riku Katainen; Minna Taskinen; Soili Kytölä; Sirpa Leppä; Marja Hietala; Pia Vahteristo; Lauri A Aaltonen
Journal:  Blood       Date:  2013-03-01       Impact factor: 22.113

7.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Authors:  Andreas Rosenwald; George Wright; Wing C Chan; Joseph M Connors; Elias Campo; Richard I Fisher; Randy D Gascoyne; H Konrad Muller-Hermelink; Erlend B Smeland; Jena M Giltnane; Elaine M Hurt; Hong Zhao; Lauren Averett; Liming Yang; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; John Powell; Patricia L Duffey; Dan L Longo; Timothy C Greiner; Dennis D Weisenburger; Warren G Sanger; Bhavana J Dave; James C Lynch; Julie Vose; James O Armitage; Emilio Montserrat; Armando López-Guillermo; Thomas M Grogan; Thomas P Miller; Michel LeBlanc; German Ott; Stein Kvaloy; Jan Delabie; Harald Holte; Peter Krajci; Trond Stokke; Louis M Staudt
Journal:  N Engl J Med       Date:  2002-06-20       Impact factor: 91.245

8.  Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma.

Authors:  David D W Twa; Fong Chun Chan; Susana Ben-Neriah; Bruce W Woolcock; Anja Mottok; King L Tan; Graham W Slack; Jay Gunawardana; Raymond S Lim; Andrew W McPherson; Robert Kridel; Adele Telenius; David W Scott; Kerry J Savage; Sohrab P Shah; Randy D Gascoyne; Christian Steidl
Journal:  Blood       Date:  2014-02-04       Impact factor: 22.113

9.  Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA.

Authors:  P Silacci; A Mottet; V Steimle; W Reith; B Mach
Journal:  J Exp Med       Date:  1994-10-01       Impact factor: 14.307

10.  Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.

Authors:  Andreas Rosenwald; George Wright; Karen Leroy; Xin Yu; Philippe Gaulard; Randy D Gascoyne; Wing C Chan; Tong Zhao; Corinne Haioun; Timothy C Greiner; Dennis D Weisenburger; James C Lynch; Julie Vose; James O Armitage; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Elias Campo; Emili Montserrat; Armando Lopez-Guillermo; German Ott; H Konrad Muller-Hermelink; Joseph M Connors; Rita Braziel; Thomas M Grogan; Richard I Fisher; Thomas P Miller; Michael LeBlanc; Michael Chiorazzi; Hong Zhao; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Louis M Staudt
Journal:  J Exp Med       Date:  2003-09-15       Impact factor: 14.307

View more
  14 in total

1.  Distinct molecular profile of IRF4-rearranged large B-cell lymphoma.

Authors:  Joan Enric Ramis-Zaldivar; Blanca Gonzalez-Farré; Olga Balagué; Verónica Celis; Ferran Nadeu; Julia Salmerón-Villalobos; Mara Andrés; Idoia Martin-Guerrero; Marta Garrido-Pontnou; Ayman Gaafar; Mariona Suñol; Carmen Bárcena; Federico Garcia-Bragado; Maitane Andión; Daniel Azorín; Itziar Astigarraga; Maria Sagaseta de Ilurdoz; Constantino Sábado; Soledad Gallego; Jaime Verdú-Amorós; Rafael Fernandez-Delgado; Vanesa Perez; Gustavo Tapia; Anna Mozos; Montserrat Torrent; Palma Solano-Páez; Alfredo Rivas-Delgado; Ivan Dlouhy; Guillem Clot; Anna Enjuanes; Armando López-Guillermo; Pallavi Galera; Matthew J Oberley; Alanna Maguire; Colleen Ramsower; Lisa M Rimsza; Leticia Quintanilla-Martinez; Elaine S Jaffe; Elías Campo; Itziar Salaverria
Journal:  Blood       Date:  2020-01-23       Impact factor: 22.113

Review 2.  PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.

Authors:  Aaron Goodman; Sandip P Patel; Razelle Kurzrock
Journal:  Nat Rev Clin Oncol       Date:  2016-11-02       Impact factor: 66.675

Review 3.  Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective.

Authors:  Irtiza N Sheikh; Amr Elgehiny; Dristhi Ragoonanan; Kris M Mahadeo; Yago Nieto; Sajad Khazal
Journal:  Cancers (Basel)       Date:  2022-06-13       Impact factor: 6.575

Review 4.  Paediatric non-Hodgkin lymphoma - perspectives in translational biology.

Authors:  Bruce Shiramizu; Lara Mussolin; Wilhelm Woessmann; Wolfram Klapper
Journal:  Br J Haematol       Date:  2016-03-24       Impact factor: 6.998

5.  Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens.

Authors:  Anja Mottok; George Wright; Andreas Rosenwald; German Ott; Colleen Ramsower; Elias Campo; Rita M Braziel; Jan Delabie; Dennis D Weisenburger; Joo Y Song; Wing C Chan; James R Cook; Kai Fu; Tim Greiner; Erlend Smeland; Harald Holte; Kerry J Savage; Betty J Glinsmann-Gibson; Randy D Gascoyne; Louis M Staudt; Elaine S Jaffe; Joseph M Connors; David W Scott; Christian Steidl; Lisa M Rimsza
Journal:  Blood       Date:  2018-09-26       Impact factor: 25.476

6.  Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.

Authors:  Andrew Davies; Thomas E Cummin; Sharon Barrans; Tom Maishman; Christoph Mamot; Urban Novak; Josh Caddy; Louise Stanton; Shamim Kazmi-Stokes; Andrew McMillan; Paul Fields; Christopher Pocock; Graham P Collins; Richard Stephens; Francesco Cucco; Alexandra Clipson; Chulin Sha; Reuben Tooze; Matthew A Care; Gareth Griffiths; Ming-Qing Du; David R Westhead; Catherine Burton; Peter W M Johnson
Journal:  Lancet Oncol       Date:  2019-04-01       Impact factor: 41.316

7.  Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma.

Authors:  Yucai Wang; Kerstin Wenzl; Michelle K Manske; Yan W Asmann; Vivekananda Sarangi; Patricia T Greipp; Jordan E Krull; Keenan Hartert; Rong He; Andrew L Feldman; Matthew J Maurer; Susan L Slager; Grzegorz S Nowakowski; Thomas M Habermann; Thomas E Witzig; Brian K Link; Stephen M Ansell; James R Cerhan; Anne J Novak
Journal:  Blood Cancer J       Date:  2019-08-30       Impact factor: 11.037

8.  Immunohistochemistry with anti-MAL antibody and RNAscope with MAL probes are complementary techniques for diagnosis of primary mediastinal large B-cell lymphoma.

Authors:  Anthony Jacquier; Charlotte Syrykh; Isabelle Bedgedjian; Franck Monnien; Camille Laurent; Séverine Valmary-Degano; Pierre Brousset
Journal:  J Clin Pathol       Date:  2020-08-24       Impact factor: 3.411

9.  Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report.

Authors:  Stuart E Lacy; Sharon L Barrans; Philip A Beer; Daniel Painter; Alexandra G Smith; Eve Roman; Susanna L Cooke; Camilo Ruiz; Paul Glover; Suzan J L Van Hoppe; Nichola Webster; Peter J Campbell; Reuben M Tooze; Russell Patmore; Cathy Burton; Simon Crouch; Daniel J Hodson
Journal:  Blood       Date:  2020-05-14       Impact factor: 25.476

Review 10.  New developments in the pathology of malignant lymphoma: a review of the literature published from May 2015-September 2015.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2015-11-19       Impact factor: 0.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.